{
  "abstract": "Background and Importance Pharmaceutical consultation(PC) plays a essencial role in optimising patient follow-up through active monitoring of drug–drug interactions (DDIs), therapeutic adherence and adverse drug reactions (ADRs) – critical factors for treatment safety and efficacy. 1 In oncology, where patients receive complex regimens and multiple medications, pharmacist-led interventions can improve outcomes and prevent medication-related harm.Aim and Objectives To describe the implementation and impact of PC in the outpatient management for prostate cancer patients, assessing the frequency and severity of DDIs, adherence, and ADRs detected.Material and Methods A retrospective observational study was conducted between February 2023 and June 2025, including 88 prostate cancer patients who started outpatient treatment. The PC process comprised collection of the Best Possible Medication History, DDI assessment using UpToDate, validation of clinical parameters (weight, height, laboratory tests), and patient education. Follow-up PC were conducted 15–30 days after treatment initiation to assess ADRs and adherence, and periodic consultations tailored to drug and patient profile. Severe DDIs and ADRs were communicated to the physician and documented in the clinical diary.Results Of 88 patients (mean age 76.9 ± 8.2 years), 70 received abiraterone, 8 apalutamide, six enzalutamide, three darolutamide, and one olaparib. A total of 294 consultations were performed (mean = 3.34 per patient). Thirty-six DDIs were identified: six class X, five class D, 25 class C. Class X interactions led to therapy modification. Overall, 30.5% were clinically relevant (classes D and X). Poor adherence (dispensation < 90% of prescribed medication) occurred in six patients, one due to ADRs. Thirty-eight patients experienced ADRs, mainly xerostomia (n=4), hepatic transaminase elevation (n=4; leading to drug discontinuation), peripheral oedema (n=9), gastrointestinal symptoms (n=10), urinary complaints (n=5), asthenia/myalgia (n=7), and rash (n=2). Nineteen patients remain under follow-up; 67 were discharged due to stability, progression, ADRs, death, or loss to follow-up.Conclusion and Relevance PC in oncology outpatients enables early detection of DDIs and ADRs and improves therapeutic adherence, contributing to safer and more effective pharmacotherapy. The structured follow-up process strengthens collaboration between pharmacists and physicians and reinforces the pharmacist’s role in optimising cancer care.References and/or Acknowledgements 1. Herborg H, Haugbølle LS, Frøkjær B, et al. Pharmacist-led medication review in outpatient clinics: a systematic review. Basic Clin Pharmacol Toxicol. 2018;122(5):518–28.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Garcia De Orta Hospital, Pharmaceutical Services, Lisboa, Portugal"
      ],
      "name": "AM Brito"
    },
    {
      "affiliations": [
        "Garcia De Orta Hospital, Pharmaceutical Services, Lisboa, Portugal"
      ],
      "name": "A Fernandes"
    },
    {
      "affiliations": [
        "Garcia De Orta Hospital, Pharmaceutical Services, Lisboa, Portugal"
      ],
      "name": "T Mendes"
    },
    {
      "affiliations": [
        "Garcia De Orta Hospital, Pharmaceutical Services, Lisboa, Portugal"
      ],
      "name": "A Alcobia"
    }
  ],
  "title": "4CPS-283 Pharmaceutical consultation in outpatient care: experience in the follow-up of patients with prostate cancer",
  "uid": "0be52b6e-ea8d-5a30-9714-6ad2990df0df"
}